Literature DB >> 2972631

Etofenamate and transcutaneous electrical nerve stimulation treatment of painful spinal syndromes.

R Coletta1, F Maggiolo, S Di Tizio.   

Abstract

Thirty patients suffering from painful syndromes of the spine were admitted to a randomized controlled clinical trial. They were divided into two groups and treated either with transcutaneous electrical nerve stimulation (TENS), one application every other day, for 20 days or with TENS and an ointment containing etofenamate 10% gel, 3-5 cm daily on the day of TENS therapy, and the same dose twice daily on the other days. The associated therapy achieved, when compared with TENS alone, a statistically significant better outcome. Furthermore a marked improvement of symptoms was observed in a shorter period of time. Therapy was well tolerated and in only four cases mild, self-limiting, skin reactions were observed. On the basis of these results the use of etofenamate and TENS could represent a viable alternative to systemic nonsteroidal antiinflammatory drug therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972631

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  3 in total

Review 1.  Transcutaneous electrical nerve stimulation for acute pain.

Authors:  Mark I Johnson; Carole A Paley; Tracey E Howe; Kathleen A Sluka
Journal:  Cochrane Database Syst Rev       Date:  2015-06-15

Review 2.  Characterising the Features of 381 Clinical Studies Evaluating Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Relief: A Secondary Analysis of the Meta-TENS Study to Improve Future Research.

Authors:  Mark I Johnson; Carole A Paley; Priscilla G Wittkopf; Matthew R Mulvey; Gareth Jones
Journal:  Medicina (Kaunas)       Date:  2022-06-14       Impact factor: 2.948

3.  A randomized trial of chiropractic manipulation and mobilization for patients with neck pain: clinical outcomes from the UCLA neck-pain study.

Authors:  Eric L Hurwitz; Hal Morgenstern; Philip Harber; Gerald F Kominski; Fei Yu; Alan H Adams
Journal:  Am J Public Health       Date:  2002-10       Impact factor: 9.308

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.